3000-03-005/ENGOT-OV44/ The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINETREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Study of TSR-042 and Niraparib in Treatment of Stage III or IV Epithelial Ovarian Cancer
Sponsor: TESARO, Inc.
Enrolling: Female Patients Only
IRB Number: AAAS0882
U.S. Govt. ID: NCT03602859
Contact: Reena Vattakalam: 212-342-6895 / rmv2110@cumc.columbia.edu
Additional Study Information: This study is being done to determine if adding the investigational drugs (TSR-042 and niraparib) to standard of care treatment delays or prevents ovarian cancer recurrence (prevents the ovarian cancer from coming back).
This study is closed
Investigator
June Hou, MD
Do You Qualify?
Have you been diagnosed with epithelial ovarian cancer? Yes No
Do you have State III or IV ovarian cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Reena Vattakalam
rmv2110@cumc.columbia.edu
212-342-6895
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE